NCT07346976 Investigation Into the Dynamic Variations of End-Tidal Carbon Monoxide Concentration (ETCOc) in Neonates Utilizing Non-Dispersive Infrared Spectroscopy and Its Implications for Jaundice Management
| NCT ID | NCT07346976 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Fourth Affiliated Hospital of Zhejiang University School of Medicine |
| Condition | Neonatal Hyperbilirubinemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-12-05 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-12-05 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to ascertain the diagnostic threshold of end-tidal carbon monoxide (ETCOc, adjusted for ambient CO levels) within the first three days postpartum, stratified by neonatal age at birth. Additionally, the study aims to evaluate the concordance of the risk range of ETCOc, as measured by non-dispersive infrared spectroscopy, with existing literature, and to assess the reliability of this technology in the management of neonatal hyperbilirubinemia.
Eligibility Criteria
Inclusion Criteria: 1. Newborns with gestational age of ≥ 37 weeks and birth weight of ≥ 2.5 kg; 2. Newborns delivered by either vaginal delivery or cesarean section and with hospital stay of ≥ 3 days. Exclusion Criteria: 1. History of second-hand smoke exposure within 24 hours 2. Parents smoke or are exposed to second-hand smoke.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07346976 clinical trial?
This trial is open to participants of all sexes, aged 0 Days or older, up to 28 Days, studying Neonatal Hyperbilirubinemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07346976 currently recruiting?
Yes, NCT07346976 is actively recruiting participants. Contact the research team at laibujilene@163.com for enrollment information.
Where is the NCT07346976 trial being conducted?
This trial is being conducted at Yiwu, China.
Who is sponsoring the NCT07346976 clinical trial?
NCT07346976 is sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. The trial plans to enroll 100 participants.